CFDE Data Portal | Search PURPL

	Label	Description
	PURPL Gene (Entity type)	ENSG00000250337 - p53 upregulated regulator of p53 levels
	GSE114492 GSE153671 KMT2D inhibition 6 v 8 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE138789 metformin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195568 palbociclib 2 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE146358 dopamine 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE113655 phenol 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE119978 GSE180930 cisplatin 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE207410 GSE207411 ARID1A knockdown 5 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE214931 temozolomide 4 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE80098 GSE80366 progesterone 0 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS

PURPL

ENSG00000250337 - p53 upregulated regulator of p53 levels

GSE114492 GSE153671 KMT2D inhibition 6 v 8 human dn

A Gene Set from LINCS

GSE138789 metformin 0 v 1 human up

A Gene Set from LINCS

GSE195568 palbociclib 2 v 10 human up

A Gene Set from LINCS

GSE146358 dopamine 3 v 7 human dn

A Gene Set from LINCS

GSE113655 phenol 1 v 2 human dn

A Gene Set from LINCS

GSE119978 GSE180930 cisplatin 3 v 1 human dn

A Gene Set from LINCS

GSE207410 GSE207411 ARID1A knockdown 5 v 3 human up

A Gene Set from LINCS

GSE214931 temozolomide 4 v 0 human up

A Gene Set from LINCS

GSE80098 GSE80366 progesterone 0 v 5 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.